secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-07-12T23:59:59+00:00
Accession:  0001493152-22-019049
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix doses first subjects in Phase 1 trial of inhaled DHE (PUR3100) for acute migraine
--------------------------------------------------------------------------------

- First five subjects dosed in Phase 1 trial of PUR3100, an inhaled formulation of dihydroergotamine (DHE) using iSPERSE technology.
- Phase 1 is a double-dummy, double-blinded trial assessing safety, tolerability, and PK of 3 inhaled doses vs IV DHE in 24 healthy volunteers.
- Data including safety, tolerability, and pharmacokinetics expected in Q4 2022 to guide dose selection for registration-enabling studies.
- Dr. Margaret Wasilewski, CMO, cited oral inhalation as potentially more convenient than IV or nasal DHE with fewer side effects.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/0001493152-22-019049-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222019049/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-019049

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer